CAJ | 학술논문

目的：探讨培美曲塞联合顺铂治疗晚期肺腺癌的临床疗效及安全性。方法将52例晚期肺腺癌患者随机分入A组与B组，A组患者接受培美曲赛联合顺铂静脉注入治疗，B组患者接受多西他赛联合顺铂静脉注入治疗。治疗2个周期及6个周期后评估临床疗效，并比较2组临床疗效、中位生存期及不良反应。结果 A组与B组治疗2个周期时疾病控制率差异无统计学意义（P＞0．05），治疗6个周期时A组患者疾病控制率显著高于B组（P＜0．05）。 A组与B组1年生存率分别为46．4％和37．5％（P＞0．05），中位生存期分别为10．2个月和9．7个月（P＞0．05）。血液学毒性、消化道反应及肝肾功能损害是2组的常见不良反应，其中A组血液学毒性发生率显著低于B组（P＜0．05）。结论培美曲塞或多西他赛联合顺铂治疗晚期肺腺癌临床疗效相当，但培美曲塞安全性更为理想，患者耐受性好。
목적：탐토배미곡새연합순박치료만기폐선암적림상료효급안전성。방법장52례만기폐선암환자수궤분입A조여B조，A조환자접수배미곡새연합순박정맥주입치료，B조환자접수다서타새연합순박정맥주입치료。치료2개주기급6개주기후평고림상료효，병비교2조림상료효、중위생존기급불량반응。결과 A조여B조치료2개주기시질병공제솔차이무통계학의의（P＞0．05），치료6개주기시A조환자질병공제솔현저고우B조（P＜0．05）。 A조여B조1년생존솔분별위46．4％화37．5％（P＞0．05），중위생존기분별위10．2개월화9．7개월（P＞0．05）。혈액학독성、소화도반응급간신공능손해시2조적상견불량반응，기중A조혈액학독성발생솔현저저우B조（P＜0．05）。결론배미곡새혹다서타새연합순박치료만기폐선암림상료효상당，단배미곡새안전성경위이상，환자내수성호。
Objective To explore the efficacy and safety of pemetrexed combined with cisplatin for advanced lung ade -nocarcinoma .Methods 52 cases of advanced lung adenocarcinoma were randomly divided into group A and group B .Group A was given pemetrexed combined with cisplatin administered intravenously .Group B received docetaxel and cisplatin administered intravenously .The clinical effects were evaluated on 2 cycles and 6 cycles after treatments .Clinical effect , median survival time and adverse reactions were compared between the 2 groups.Results There were no significant difference in disease control rate between group A and group B on 2 cycles after treatment (96.4%vs 91.7%,P>0.05);The disease control rate in group A on 6 cycles after treatment was much higher than that of group B (46.4% vs 20.8%,P<0.05);1-year survival rate were 46.4%and 37.5%(P>0.05),median survival time was 10.2 months and 9.7 months in group A and group B(P>0.05);Hematologic toxicities,gastrointestinal reactions and liver renal toxicity were the main adverse reactions in 2 groups.The hematologic toxicities and gastrointestinal reactions in group A were much lower than those of group B (P<0.05).Conclusion Pemetrexed or do-cetaxel combined with cisplatin showed similar efficacy for advanced lung adenocarcinoma .Pemetrexed has better safety and toler-ability.